Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
5.76
-0.50 (-7.99%)
Jul 18, 2025, 4:00 PM - Market closed
Actuate Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Actuate Therapeutics stock has a target of 20, which predicts a 247.22% increase from the current stock price of 5.76.
Price Target: $20 (+247.22%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 17, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Actuate Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 |
|---|---|---|
| Strong Buy | 1 | 1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +247.22% | Mar 17, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.28
from -3.26
EPS Next Year
-1.54
from -1.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | n/a |
| Avg | n/a | n/a | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.26 | -1.42 | -1.70 |
| Avg | -1.28 | -1.54 | -2.20 |
| Low | -1.28 | -1.64 | -2.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.